期刊
IMMUNOLOGIC RESEARCH
卷 57, 期 1-3, 页码 151-158出版社
HUMANA PRESS INC
DOI: 10.1007/s12026-013-8464-1
关键词
Memory; CCR7; Asthma; Colitis; Mucosal immunity; Th17; Hodgkin; ALCL
类别
资金
- NCI NIH HHS [R01 CA080228] Funding Source: Medline
The FDA recently approved an agonistic anti-CD30 drug conjugate, Brentuximab vedotin, for the treatment for CD30-positive lymphomas. The potent clinical activity of Brentuximab vedotin in Hodgkin's lymphoma and anaplastic large-cell lymphoma was greeted with great enthusiasm by oncologists as it provided a new treatment modality for these diseases. In this review, we will describe how we obtained the hybridoma by pursuing a basic research experiment unrelated to CD30. I will also review what we know about the normal biological functions of CD30 that were studied primarily in murine models of disease but also in patients. The picture emerging is that one of the primary functions of CD30 is the control of memory cells providing costimulation and trafficking information or inducing apoptosis in a microenvironment and cytokine milieu-dependent manner.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据